Abstract:Traditional cancer therapies, such as surgery treatment, radiotherapy, and chemotherapy, often fail to completely eliminate tumor cells in an anaerobic microenvironment of tumor regions. In contrast to these traditional cancer therapies, the use of targeted delivery vectors to deliver anticancer genes or antitumor drugs to hypoxic areas in tumors is the most clinically promising cancer treatment with rapid development in recent years. In this study, E.coli Nissle 1917 (EcN), an intestinal probiotic, was utilized as a targeted transport vector to deliver p53 and Tum-5 protein to tumor hypoxic regions. The tumor-targeting characteristics of EcN were investigated using luciferase Lux CDABE operon, and the results demonstrated that EcN could specifically accumulate in the solid tumor areas of SMMC-7721 tumor-bearing BALB/c nude mice. The Tum 5-p53 bifunctional proteins were initially constructed and then delivered to solid tumor regions by using the targeted transporter EcN for cancer therapy. The antitumor effect and safety of three engineered bacteria, namely, EcN (Tum-5), EcN (p53), and EcN (Tum 5-p53), were also examined. The calculated tumor volume and tumor weight indicated that these three engineered bacteria could inhibit the growth of human hepatoma SMMC-7721 cells, and the antitumor effect of EcN (Tum 5-p53) expressing the Tum 5-p53 fusion protein was significantly better than those of EcN (Tum-5) and EcN (p53) alone. Immunofluorescence demonstrated that the expression of Ki-67, a nuclear proliferation-related protein, was inhibited in the tumor areas of the groups treated with the engineered bacteria, whereas the expression of caspase-3 was upregulated. The expression trends of Ki-67 and caspase-3 were consistent with the different antitumor efficacies of these three engineered bacteria. EcN did not elicit obvious side effects on mice. This research not only provids a foundation for tumor-targeted therapy but also contributes greatly to the development of antitumor agents and anticancer proteins.

Engineered probiotic E.coli Nissle 1917 for release PTEN to improve the tumor microenvironment and suppress tumor growth

Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy

Tumor-targeting engineered probiotic Escherichia coli Nissle 1917 inhibits colorectal tumorigenesis and modulates gut microbiota homeostasis in mice

Chemically Enhanced Live Probiotic for in Vivo Tumor Targeting and Inhibition

Non-pathogenic Trojan horse Nissle1917 triggers mitophagy through PINK1/Parkin pathway to discourage colon cancer

Engineering Probiotic E. coli Nissle 1917 for Release of Therapeutic Nanobodies

Bioengineered Escherichia coli Nissle 1917 for tumour‐targeting therapy

Tumor Colonization and Therapy by Escherichia coli Nissle 1917 Strain in Syngeneic Tumor-Bearing Mice Is Strongly Affected by the Gut Microbiome

Expressing Cytotoxic Compounds in Escherichia Coli Nissle 1917 for Tumor-Targeting Therapy.

Metabolic engineering of probiotic Escherichia coli for cytolytic therapy of tumors

Self-adjusting Engineered Probiotic for Targeted Tumor Colonization and Local Therapeutics Delivery

Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia

Oral Probiotics Microgel Plus Galunisertib Reduced TGF-β Blockade Resistance and Enhanced Anti-tumor Immune Responses in Colorectal Cancer

Towards Understanding Tumour Colonisation by Probiotic Bacterium E. coli Nissle 1917

Enhancing tumor-specific recognition of programmable synthetic bacterial consortium for precision therapy of colorectal cancer

Spatiotemporal Delivery of Dual Nanobodies by Engineered Probiotics to Reverse Tumor Immunosuppression via Targeting Tumor-Derived Exosomes

“Tumor-selective treatment of metastatic pancreatic cancer with an engineered, probiotic living drug”

<i>Escherichia</i><i>coli</i> Nissle 1917 as a Novel Microrobot for Tumor-Targeted Imaging and Therapy

Anti-cancer properties of Escherichia coli Nissle 1917 against HT-29 colon cancer cells through regulation of Bax/Bcl-xL and AKT/PTEN signaling pathways

Engineering Clinically Relevant Probiotics with Switchable "nano‐promoter" and "nano‐effector" for Precision Tumor Therapy

Genetically engineered probiotics for an optical imaging-guided tumor photothermal therapy/immunotherapy